Wholesale GLP-1 class peptides, with the scrutiny priced in.

Which GLP-1 class compounds the catalogue lists

The Primara Labs catalogue lists three compounds in its metabolic and incretin category, each supplied as a lyophilised powder in a sealed vial, with sizes as set out below. Each product page carries the compound's regulatory status line, what it is, and the published price.

• Retatrutide

  Listed as a 20mg vial. Triple agonist at the GLP-1, GIP and glucagon receptors. Studied in Phase 2 obesity trials. See the retatrutide page.

• Tirzepatide

  Listed as a 15mg vial. Dual GIP and GLP-1 receptor agonist with an extensive published trial record. See the tirzepatide page.

• Semaglutide

  Listed as a 15mg vial. Single GLP-1 receptor agonist, the most extensively published compound in the incretin class. See the semaglutide page.

Every published price for these compounds, including the five and ten vial pack rates, sits on the pack pricing page. Nothing in this guide adds to or undercuts those figures, and no wholesale tier is printed anywhere on the site.

Why these are the highest-demand compounds

GLP-1 class compounds are the most requested peptides in the Philippine market because they are the most discussed compounds in the world. The registered medicines in this class have been in the news for years, the trial programmes behind them are large and widely reported, and a great deal of that coverage reaches Filipino buyers through social media long before it reaches a clinic.

For a reseller or a practice that has noticed the demand, the commercial pull is obvious. The same compound names come up in enquiries every day, the questions are repetitive, and the buyers are often ready to order. That is exactly the profile that makes people want to buy in volume.

Demand is not the same as a good business, though. A compound that everyone asks about is also a compound everyone else is selling, a compound regulators and platforms are watching, and a compound whose buyers are most likely to be thinking about human use. All three of those land on the reseller, not on the search trend.

Why they also draw the most scrutiny

GLP-1 class vials draw more scrutiny than any other peptide category in the Philippines because they sit right next to a registered, prescription-only medicine class. A research-use-only vial of a compound that also exists as a pharmacy product is the easiest thing in the market for a regulator, a platform or a journalist to notice.

The scrutiny comes from several directions at once. The Philippine FDA issues advisories on unregistered health products as it sees fit. Online marketplaces and social platforms apply their own rules to weight-related products. Payment providers watch for categories they consider high risk. And buyers themselves are more likely to be anxious, first-time and outcome-focused than buyers of any other compound.

None of that is a reason this guide will tell anyone how to stay under the radar. It will not. It is a reason to be clear about the position before ordering: these compounds are supplied for research use only, they are not approved for human use in the Philippines, and a seller who markets them for weight loss is making outcome claims of their own and carrying the consequences of them.

The regulatory landscape in the Philippines

In the Philippines, registered incretin medicines are prescription drugs dispensed through licensed pharmacies against a doctor's prescription, under FDA Philippines oversight. Research-use-only vials are not registered drug products and are not approved for human use. That is the current position, and GLP-1 regulations in the Philippines in 2026 sets it out in more detail.

Retatrutide is a different case from the other two, because it is investigational everywhere. Its phase 3 programme, TRIUMPH, is still running, and the regulatory position is plain: No FDA Philippines registration. No branded product exists in any market. There is no pharmacy route for it at all, only trial supply and research-use-only supply.

The governing statute for health products is Republic Act 9711, the Food and Drug Administration Act of 2009, which among other things requires health products to be registered and establishments that distribute or sell them to be licensed. How that applies to any particular business, and particularly to a clinic or reseller supplying patients or the public, is a question for your own lawyer and tax adviser rather than for a supplier's guide.

The framework can change. Regulators in several countries have moved against unregistered GLP-1 products in recent years, and a volume buyer holding months of stock is more exposed to a change than a buyer holding a pack. Treat the current position as a snapshot. What research use only means explains the designation itself.

What volume buyers ask first: allocation

The first thing serious volume buyers ask about GLP-1 class compounds is allocation, because these are the compounds most likely to run short when demand spikes.

Allocation means a quantity is held against your run rate rather than sitting in the general pool, where it goes to whoever orders next. For a reseller or a practice whose customers come back for the same compound, that is usually worth more than any price movement, because telling a repeat buyer that something is out costs more than the margin on one order.

Allocation is set from what you actually move, so the useful first message gives a real monthly figure, not a target. An invented run rate produces an allocation that is wrong in one direction or the other: too little and it does nothing, too much and you are holding stock you do not turn over. How a reseller account works covers allocation and reorder cadence in full, and buying peptides above a ten pack covers why volume moves the number.

Batch consistency and batch numbers

Every vial Primara ships carries a batch number, which is what makes a large GLP-1 order traceable vial by vial rather than as an undifferentiated box.

For a volume buyer the practical questions are which batch an order or an allocation comes from, whether a large order is drawn from one batch or several, and how a question about a specific vial is handled. Ask all three in the first conversation. Message the batch number on any vial and you are told which run it came from.

Lab reports are published per batch when issued, on the lab reports page, with the scope of each report stated on the report row. The trust page explains how Primara handles batches and documents. Do not put any wording about testing on your own listings beyond what a published report covers, scoped the way the report scopes it: that would be your claim rather than ours.

Choosing vial sizes for volume

Vial size is a stock decision for a volume buyer, not just a price decision, and the right answer depends on who the vials are for.

• Per milligram

  Larger vials usually work out differently per milligram. Compare on the pack pricing page, where the peso per milligram is worked out at the deepest tier, rather than comparing vial prices.

• What your buyers recognise

  Repeat buyers anchor on a size. Switching sizes partway through a customer relationship generates questions, and labelling and records have to change with it.

• Reconstitution arithmetic

  A different amount in the vial means a different concentration for the same volume of water, so labels and records change with the size. The site's reconstitution calculator does that arithmetic on numbers you enter and never suggests an amount.

• Stock count

  Fewer, larger vials take less fridge space and fewer records for the same total amount, which matters at volume.

Where a second size is listed with limited stock, plan around the primary size and treat the second as a bridge rather than a standing line.

Storage and delivery for large orders

Holding GLP-1 class stock in volume means holding it cold, dark and undisturbed, in a dedicated fridge rather than a shared one. Sealed lyophilised powder is stable in a freezer and tolerates a fridge; once reconstituted, a vial belongs in the fridge and should not be frozen.

Philippine conditions add their own risks. A brownout in April can warm a domestic fridge faster than most people expect, so keep the door shut during an outage and do not move stock into a car or a hot room in the meantime. A fridge opened dozens of times a day cycles far more than one opened twice. Storing peptide stock in the Philippines covers heat, outages and handling.

Every order ships in insulated packaging with a cold pack and plain outer packaging. Metro Manila orders confirmed before the cutoff on a weekday arrive the same day; the rest of the country is 1 to 5 business days by region, and parcels for the Visayas and Mindanao leave Monday to Wednesday only, so a vial is never sitting in a courier hub over a weekend. Full detail is on the delivery page. Bacteriostatic water, syringes, pads, a reconstitution syringe and blank labels ship with every order at every size, as set out on what ships in the box.

What not to say when reselling GLP-1 class compounds

A reseller of GLP-1 class compounds in the Philippines should describe them by what they are, never by what they do to anyone, and should never position a vial against a pharmacy medicine.

This is where most of the risk in this category is created, and it is created by sellers rather than by suppliers. The temptation is strongest here because the buyers are asking outcome questions, and an outcome answer closes the sale.

• No weight or outcome claims

  No kilograms, no before-and-after photos, no testimonials that attribute a result to a vial. A third party's trial finding repeated in your own sales message becomes your claim.

• No dosing or schedules

  No charts, amounts or schedules, in a caption, a chat or a voice note. If a buyer needs that, the answer is a doctor.

• No pharmaceutical comparisons

  No branded medicine names, no 'same as', no price comparison against a pharmacy product. That framing invites exactly the scrutiny this guide describes.

• No testing wording you cannot point to

  Only what a published report covers, scoped the way the report scopes it, and linked rather than paraphrased.

What peptide resellers should never say covers the full list across every compound.

How to enquire about GLP-1 wholesale

To enquire about retatrutide, tirzepatide or semaglutide in volume, message Primara on WhatsApp with the compound, the vial size, the realistic monthly quantity and how often you would reorder.

Check the pack pricing page first. If a ten pack covers what you move, that is already the best published number and an account adds nothing to it. Above a pack, terms are quoted against your actual order in the same thread, with no published tier, minimum or margin. Say whether you are a reseller or a clinic, where you are based, and whether you need a registered invoice.

Expect to be asked what you plan to say to your own buyers. A plan that depends on weight-loss claims, dosing guidance or pharmaceutical comparisons is not one Primara will supply into, and it is better to find that out in the first reply than after the stock has landed.